What MOTS-c, SS-31 and 5-Amino-1MQ actually do, why they are not one stack, and how little human evidence exists behind the mitochondrial peptide claims.
25 min read
MOTS-c, SS-31 and 5-Amino-1MQ are sold together as a mitochondrial stack because all three touch the cell's energy system. They are not the same class of compound, they do not act on the same target, and their evidence bases are nowhere near equal. This guide separates them properly, grades every claim by the strongest model it has actually been shown in, and corrects several things the previous edition got wrong, including calling SS-31 an antioxidant and claiming it had no reported side effects.
What's Inside
Written for adults weighing mitochondrial peptides who want the evidence graded honestly rather than sold to them, and for coaches fielding questions about them. It assumes you understand the difference between a mouse study and a human trial, and that any decision here involves a clinician and baseline bloodwork. It is not a protocol, and it is explicit that for two of the three compounds, every dose in circulation is an extrapolation.
Three different jobs. MOTS-c is a sixteen-amino-acid peptide encoded inside mitochondrial DNA itself, and it behaves like a signal from the mitochondrion to the rest of the cell, acting through the folate cycle to raise AMPK activity, with skeletal muscle as its main target. Under metabolic stress it can also move into the nucleus and switch on antioxidant stress-response genes. SS-31, also known as elamipretide, is a synthetic four-amino-acid peptide that concentrates in the inner mitochondrial membrane and binds cardiolipin, the phospholipid that holds the electron transport complexes together. That distinction matters: it is not an antioxidant mopping up free radicals after the fact, it reduces them at source by keeping electron transfer tight, which is also why its effects are largest in damaged or aged mitochondria and smallest in healthy young ones. 5-Amino-1MQ is not a peptide at all. It is a small molecule that inhibits NNMT, an enzyme concentrated in white fat and liver tissue, with the idea being that blocking it spares NAD precursors and methyl donors so fat cells spend more energy.
Very little, and it is distributed unevenly. SS-31 is the only one of the three with human trial data, including trials in primary mitochondrial myopathy and a narrow regulatory approval, which also produced the side effect profile the earlier edition missed: injection-site reactions are the most common adverse event, alongside headache and temporary fatigue. MOTS-c has no published human efficacy trial at all. What exists is strong mechanistic work plus mouse studies, where injected MOTS-c raised running capacity in young and old animals, prevented diet-induced obesity and reversed age-related insulin resistance, and one genuinely human finding that endogenous MOTS-c rises with exercise. An analogue reached early-phase human testing, which is not the same thing. 5-Amino-1MQ sits in the same position: NNMT knockdown protected mice from diet-induced obesity, the compound reproduced that effect pharmacologically in obese mice, and it activated muscle stem cells in aged mice, but there is no human efficacy trial and no hypertrophy data in any species. The Peptide Database grades each one against the same standard.
The rationale is coherent and the data does not exist. On paper the three cover different levers: MOTS-c sends the metabolic signal, SS-31 protects the machinery that signal runs on, and 5-Amino-1MQ changes fuel handling in fat tissue. Pairing MOTS-c with SS-31 is the most mechanistically sensible combination of the set, since one raises demand for capacity while the other improves the efficiency of existing machinery. But no combination of these compounds has been tested together in any species, so every stack is reasoning rather than evidence, and stacking multiplies unknowns, which is why starting one compound at a time is the only way any reaction has a traceable cause. The honest framing for fat loss in particular is that neither MOTS-c nor 5-Amino-1MQ replaces the calorie deficit, which still does the heavy lifting. The Peptide Stack Builder checks interactions and what any given combination actually requires in monitoring.
Mostly not the pharmacology in the papers. The largest practical risk with all three is the vial itself, because a research-chemical supply chain brings documented problems with under-dosing, wrong compounds, contamination and endotoxin, which is why third-party identity and purity testing on the specific batch matters more than any dosing nuance. Tested athletes should treat all three as prohibited and check the current year's list, since non-approved substances and metabolic modulators both fall under it. MOTS-c carries a low blood sugar risk that becomes additive with insulin, sulfonylureas, GLP-1 drugs, metformin or berberine, and is highest when fasted. Injection technique brings the usual infection risk, where spreading redness, heat or fever needs same-day medical review rather than waiting. SS-31 exposure rises with reduced kidney function, so kidney markers belong in the baseline. Both MOTS-c and 5-Amino-1MQ alter core metabolic signalling with unstudied effects on tumours, which makes active cancer or a cancer history an absolute exclusion. The Blood Test Selector builds the baseline panel and the Bloodwork Analyzer reads it, because with compounds this under-studied, labs rather than feel are the only way to know whether anything happened.
The full guide covers the mechanism of each compound with diagrams, every original claim graded by its evidence level, a complete dosage evidence review labelling each figure as community practice, trial dose or approved label, stacking and comparisons, the full risk classification, the monitoring panel, a seven-gate decision framework, troubleshooting and the reference list. Download the PDF for the complete reference.
This page and the full guide are for educational purposes only. They are not medical advice, a prescription or a recommendation to use any compound. None of these three is approved for performance, fat loss or ageing, and MOTS-c and 5-Amino-1MQ have no published human efficacy trial, so any circulating dose for them is extrapolation rather than evidence. All three should be treated as prohibited by tested athletes. They are not for anyone under 18, pregnant or breastfeeding, or with active cancer, a cancer history, or severe kidney or liver disease, and anyone on glucose-lowering medication needs medical oversight. Do not start, stop or change any compound without a qualified clinician.
No human efficacy trial has been published. The performance and metabolic findings come from mouse studies, though the rise in natural MOTS-c after exercise has been confirmed in people.
Not in the usual sense. It binds cardiolipin in the inner mitochondrial membrane and reduces free radicals at source by keeping electron transfer tight, rather than neutralising them afterwards.
No, it is a small molecule that inhibits the NNMT enzyme in fat and liver tissue. It is frequently sold alongside peptides, which is where the confusion comes from.
The rationale is coherent, but no combination of them has been tested together in any species. Running one at a time is the only way to attribute any effect or reaction.
This guide is for educational purposes only and is not medical advice.
Newsletter
One email when a new guide, calculator or breakdown goes live. Nothing else.
